Log in to search using one of your social media accounts:

 

NovoCure rises on Q3 EPS, sales beat

Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results. The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year. Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street. “The third quarter of 2017 was another period marked by growth across all key commercial metrics in all key markets. Compared to the same quarter in 2016, we achieved 131% revenue growth – our ninth consecutive quarter of triple-digit year-over-year growth – and 71% active patient growth. We significantly improved net revenues as a percentage of gross billings year-over-year and generated positive cash flow from operations for the first time in the company’s history. Optune is the first treatment in more than 10 years to increase median overall survival in newly diagnosed GBM, and we are focused on bringing Optune to as many patients with glioblastoma who may benefit from it,” CEO Asaf Danziger said in a press release. The company updated on clinical trial milestones, expecting to launch phase 3 pivotal trials in loc...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news

Related Links:

Abstract Receptor tyrosine kinases (RTKs) such as the insulin-like growth factor type 1 receptor (IGF-1R) control important biological activities as well as being involved in pathological processes. Due to their supportive nature in many human cancers they have long been considered attractive therapeutic targets. However, lessons learnt from early targeting trials highlight that a simple "active versus inactive" state model with classical kinase-only signaling is overly simplistic and does not describe reality. A vast amount of evidence exists disproving this model and hence provides a rational explanati...
Source: International Review of Cell and Molecular Biology - Category: Cytology Authors: Tags: Int Rev Cell Mol Biol Source Type: research
M árcio Debiasi, Carisi A. Polanczyk, Patrícia Ziegelmann, Carlos Barrios, Hongyuan Cao, James J. Dignam, Paul Goss, Brittany Bychkovsky, Dianne M. Finkelstein, Rodrigo S. Guindalini, Paulo Filho, Caroline Albuquerque, Tomás Reinert, Evandro de Azambuja, Olufunmilayo Olopade
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Hung-Ming Lam, Eva Corey
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Contributors : Feng Zhou ; Shuai Gao ; Dong Han ; Changmeng CaiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe aberrant activation of the ERG oncogenic pathway due to TMPRSS2-ERG gene fusions is the major driver of prostate cancer initiation and progression. We identified the alpha1 and beta1 subunits of soluble guanylyl cyclase (GUCY1A1, GUCY1B1) as major ERG-regulated genes in prostate cancer cells. Soluble guanylyl cyclase (sGC) is the major mediator of nitric oxide signaling in cells that, upon nitric oxide binding, catalyzes the synthesis of cGMP and subsequently activates PK...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Consolidating all Medicare drug payments under Part D sounds easy, but some cancer patients fear they'll take a hit
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
In this study, a comprehensive dielectric spectroscopy study is conducted for the first time to characterize the ultra-wideband dielectric properties of freshly excised normal and malignant skin tissues obtained from skin cancer patients having undergone Mohs micrographic surgeries at Hackensack University Medical Center. Measurements are conducted using a precision slim-form open-ended coaxial probe in conjunction with a millimeter-wave vector network analyzer over the frequency range of 0.5–50 GHz. A one-pole Cole–Cole model is fitted to the complex permittivity dataset of each sample. Statistically considera...
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Drinkers in particular need to be more aware of mounting evidence of links between alcohol and cancer, and make judgements accordingly
Source: New Scientist - Health - Category: Consumer Health News Source Type: research
Pamela North was referred to hospital by her GP with suspected bladder cancer in February 2015. The grandmother from Ilford, Essex, was diagnosed a year later but died in 2016.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
In this study, we investigated the role of the PIM kinases with respect to T cell responses in transplantation and tumor immunity. We found that the PIM-2 isoform negatively regulated T cell responses to alloantigen, in contrast to the PIM-1 and PIM-3 isoforms, which acted as positive regulators. T cells deficient in PIM-2 demonstrated increased T cell differentiation toward Th1 subset, proliferation, and migration to target organs after allogeneic bone marrow transplantation, resulting in dramatically accelerated graft-versus-host disease (GVHD) severity. Restoration of PIM-2 expression markedly attenuated the pathogenici...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Looking to detect cancer early through a simple blood test, Grail Inc. raised a $300 million from several Chinese investors on top of $1.2 billion in two earlier rounds over the past two years. The Menlo Park company, which has been rumored to be planning a $500 million initial public offering in Hong Kong later this year, said the oversubscribed Series C round will help it develop and validate experimental products for early cancer detection. A year ago, it bought Chinese blood diagnos tics company…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
More News: Asbestosis | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Lung Cancer | Medical Devices | Mesothelioma | Neurology | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Profits and Losses